---
title: Unlocking Unprecedented Market Access Through Government-Funded Clinical Trials
description: How pharmaceutical companies can leverage Medicare/Medicaid funding to dramatically reduce R&D costs while accessing the entire US market.
---

# Executive Summary: The $100B+ Opportunity

The proposed decentralized FDA (dFDA) platform enables pharmaceutical companies to access **government funding for clinical trials** while simultaneously gaining access to an unprecedented patient pool of **150.8M Medicare and Medicaid beneficiaries** ([CMS, 2024](https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet)).

## Key Financial Benefits

1. **Elimination of Trial Costs**
   - Current Phase 3 trial median cost: **$19-21.4M** ([Johns Hopkins, 2018](https://publichealth.jhu.edu/2018/cost-of-clinical-trials-for-new-drug-FDA-approval-are-fraction-of-total-tab))
   - Higher estimates reach **$255M** per trial ([Tufts, 2014](https://www.appliedclinicaltrialsonline.com/view/new-research-emerges-challenge-steep-costs-clinical-trials))
   - Government funding eliminates these costs entirely

2. **Patient Recruitment Savings**
   - Current recruitment cost: **$6,533 per patient** 
   - Dropout replacement cost: **$19,533 per patient**
   - Source: [Cell & Gene, 2024](https://www.cellandgene.com/doc/clinical-trial-recruitment-0001)
   
3. **Massive Market Access**
   - Medicare: **59.6M beneficiaries** ([KFF, 2024](https://www.kff.org/medicare/issue-brief/a-snapshot-of-sources-of-coverage-among-medicare-beneficiaries/))
   - Medicaid: **91.2M beneficiaries** ([CMS, 2024](https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet))
   - Instant access to **150.8M potential patients**

## Financial Model: Cost Savings Per Drug

| Cost Category | Traditional Model | dFDA Model | Savings |
|--------------|------------------|------------|---------|
| Phase 3 Trial | $21.4M | $0 | $21.4M |
| Patient Recruitment (10,000 patients) | $65.3M | $0 | $65.3M |
| Dropout Replacement (15%) | $29.3M | $0 | $29.3M |
| **Total Savings** | | | **$116M** |

# Legal Framework

Under existing **FDA regulations ([21 CFR 312.8](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/section-312.8))**, companies can:
- Charge per-participant fees to cover direct costs
- Include employee salaries and operational expenses
- Maintain compliance without pre-approval

# Implementation Steps

1. **Set Per-Participant Price**
   - Cover manufacturing costs
   - Include operational expenses
   - Factor in employee compensation
   
2. **Access Government Funding**
   - Medicare/Medicaid reimbursement
   - NIH trial funding
   - Automated payment processing

3. **Scale Trial Operations**
   - Instant access to 150.8M patients
   - Automated matching and enrollment
   - Real-time monitoring and adjustments

# ROI Analysis

| Metric | Traditional | dFDA Platform |
|--------|------------|---------------|
| Time to Market (Phase 3 + Approval) | 4.6 years | 2-3 years |
| Patient Access | Limited | 150.8M instant |
| Trial Costs | $116M+ | $0 |
| Market Entry | Gradual | Immediate |

# Next Steps

1. Review your trial portfolio for government funding eligibility
2. Calculate potential savings using our ROI calculator
3. Schedule a consultation to begin implementation

Contact: [email protected] for detailed financial modeling based on your specific pipeline.

---

*Note: All figures based on publicly available data and peer-reviewed research. Individual results may vary based on therapeutic area and trial complexity.*
